University of California San Francisco
Give to UCSFUCSF-led research outlines the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. Their findings could reveal the mechanism of neoplastic progression and provide targets for immunotherapy to inhibit progression or treat invasive disease.
Pregnant women in the U.S. are being exposed to chemicals like melamine, cyanuric acid, and aromatic amines that can increase the risk of cancer and harm child development, according to a study from researchers at UCSF and Johns Hopkins Bloomberg School of Public Health.
T cells used in immunotherapy treatments can get exhausted and shut down by fighting cancer cells and tumors. Using a CRISPR-based edit on these cells’ genomes, researchers at UCSF and Gladstone Institutes have rendered the therapeutic cells more resilient against tumors.
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
In a groundbreaking finding, a new study led by UCSF found that routine screening for and removal of precancerous anal lesions can significantly reduce the risk of anal cancer, similar to the way cervical cancer is prevented in women.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
Companies claim there’s bad stuff in our homes and bodies, and we should pay to purge it. What’s worth worrying over?
As a worldwide shortage of contrast dye for medical imaging continues, a new UCSF research letter in JAMA quantified strategies to safely reduce dye use in computed tomography (CT) by up to 83%. CT is the most common use for the dye.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.
Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute, examines in detail the effects of a handful of genes that seem to play an outsize role in a wide array of diseases.
Brain tumor patients survived longer when treated aggressively with surgery, radiation and chemotherapy. Now, a UCSF study underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
UCSF researchers found that cancers from different parts of the body are immunologically similar to one another. They described 12 classes of "immune archetypes" to classify cancer tumors, which can provide unique strategies for enhancing patients’ choice of cancer immunotherapies.
For patients with skin cancer & facial sarcoma, reconstructing the face with skin grafted from the leg may result in poor color match. A new technique pioneered by UCSF surgeons uses pigmented tissue to achieve a better match.
Helen Diller Family Cancer Research BuildingExperts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most
The UCSF initiative aims to increase the effectiveness and availability of chimeric antigen receptor T-cell (CAR T) therapy for lymphoma patients.
A groundbreaking national study led by UCSF finds that treating anal cancer precursor lesions reduces cancer risk for people with HIV.
A new prostate cancer test developed by UCSF and UCLA detects cancer cells that have spread to lymph nodes both inside and outside the pelvis.
Glioblastoma is the most common malignant brain tumor and among the most treatment-resistant cancers. In the last 15 years, numerous attempts to develop new drugs for glioblastoma have failed.
Researchers at UCSF and UC San Diego have mapped out how hundreds of mutations involved in two types of cancer affect the activity of proteins that are the ultimate actors behind the disease.
Researchers at UCSF have gained insight into how cancer cells proliferate despite a myriad of stresses.
Taking a page from computer engineers, biologists are trying their hands at programming cells – by building DNA circuits to guide their protein-making machinery and behavior.
T cells – immune cells that patrol our bodies in search of trouble – have become a central focus for UC San Francisco scientists working on living cell therapies, an approach that views cells